Drug Trial Radar · NCT04616326
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
312
Actual
Start
Nov 25, 2020
Primary completion
Dec 10, 2025
Study completion Mar 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Conditions
- Chronic Migraine
Interventions
GalcanezumabDrug
Administered SQ
PlaceboDrug
Administered SQ
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Number of Monthly Migraine Headache DaysTime frame: Baseline, 3 Months
Locations
88 sites in 11 countries. Site status is shown where the registry gives one.
Rehabilitation & Neurological Services
Huntsville, Alabama
21st Century Neurology, a Division of Xenoscience, Inc.
Phoenix, Arizona
Phoenix Children's Hospital
Phoenix, Arizona
Center for Neurosciences
Tucson, Arizona
Miller Children's & Women's Hospital Long Beach
Long Beach, California
Children's Hospital Colorado
Aurora, Colorado
Northwest Florida Clinical Research Group
Gulf Breeze, Florida
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Jacksonville, Florida
Vitaly Clinical Research
Miami, Florida
EMDA Clinical Research
Miami, Florida
Bio-Medical Research LLC
Miami, Florida
Allied Biomedical Research Institute
Miami, Florida
Ezy Medical Research
Miami Lakes, Florida
Wellness Clinical Research
Miami Lakes, Florida
Avanza Medical Research Center
Pensacola, Florida
D&H Tamarac Research Center
Tamarac, Florida
Infinity Life Research Group
Tamarac, Florida
USF Health
Tampa, Florida
Palm Beach Research Center
West Palm Beach, Florida
Medical Research Partners
Ammon, Idaho
Northwest Clinical Trials
Boise, Idaho
St. Alexius Medical Center
Hoffman Estates, Illinois
Ascension Via Christi Research
Wichita, Kansas
University of Kentucky Chandler Medical Center
Lexington, Kentucky
Pharmasite Research, Inc.
Baltimore, Maryland
MedVadis Research Corporation
Waltham, Massachusetts
Minneapolis Clinic of Neurology - Burnsville Office
Burnsville, Minnesota
Precise Research Centers
Flowood, Mississippi
Proven Endpoints
Ridgeland, Mississippi
Children Mercy Pediatric Clinical Research Unit
Kansas City, Missouri
Saint Peter's University Hospital
New Brunswick, New Jersey
Dent Neurologic Institute
Amherst, New York
Cohen Children's Northwell Health Physician Partners - Pediatric Neurology
New Hyde Park, New York
Velocity Clinical Research at Raleigh Neurology
Raleigh, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Headache Center of Hope
Cincinnati, Ohio
Providence Health & Services
Portland, Oregon
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Coastal Pediatric Research
Charleston, South Carolina
Access Clinical Trials - Nashville
Nashville, Tennessee
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.